Equivalence among agents supports streptokinase where cost-effective; confirms no mortality advantage for tPA or anistreplase in AMI.
Coordinated by Dr Rory Collins from Oxford, the data for the third international study of infarct survival (ISIS-3) came from investigators in nearly 1 000 hospitals in Europe, North America, and Australasia who had treated over 46 000 patients suffering an acute myocardial infarction with one of three randomly assigned fibrinolytic agents : streptokinase, anistreplase, or tissue plasminogen activator (tPA)
No takes yet. Share an insight, caveat, or question.
Martin O’Donnell (1991) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: